594 related articles for article (PubMed ID: 26633462)
21. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy.
Mahasa KJ; de Pillis L; Ouifki R; Eladdadi A; Maini P; Yoon AR; Yun CO
Sci Rep; 2020 Jan; 10(1):425. PubMed ID: 31949228
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic virotherapy.
Cervantes-García D; Ortiz-López R; Mayek-Pérez N; Rojas-Martínez A
Ann Hepatol; 2008; 7(1):34-45. PubMed ID: 18376364
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in targeting cancer stem cells using oncolytic viruses.
Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ
Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558
[TBL] [Abstract][Full Text] [Related]
24. Questing for an optimal, universal viral agent for oncolytic virotherapy.
Paiva LR; Martins ML; Ferreira SC
Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Oct; 84(4 Pt 1):041918. PubMed ID: 22181186
[TBL] [Abstract][Full Text] [Related]
25. Development of oncolytic viruses for cancer therapy.
Abd-Aziz N; Poh CL
Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic virotherapy of breast cancer.
Hartkopf AD; Fehm T; Wallwiener D; Lauer UM
Gynecol Oncol; 2011 Oct; 123(1):164-71. PubMed ID: 21764108
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic virotherapy as a personalized cancer vaccine.
Li QX; Liu G; Wong-Staal F
Int J Cancer; 2008 Aug; 123(3):493-9. PubMed ID: 18500742
[TBL] [Abstract][Full Text] [Related]
28. The mechanisms of genetically modified vaccinia viruses for the treatment of cancer.
Jefferson A; Cadet VE; Hielscher A
Crit Rev Oncol Hematol; 2015 Sep; 95(3):407-16. PubMed ID: 25900073
[TBL] [Abstract][Full Text] [Related]
29. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
Power AT; Bell JC
Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
[TBL] [Abstract][Full Text] [Related]
30. Clinical development directions in oncolytic viral therapy.
Eager RM; Nemunaitis J
Cancer Gene Ther; 2011 May; 18(5):305-17. PubMed ID: 21436867
[TBL] [Abstract][Full Text] [Related]
31. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
32. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
33. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery.
Thorne SH; Contag CH
Gene Ther; 2008 May; 15(10):753-8. PubMed ID: 18356814
[TBL] [Abstract][Full Text] [Related]
34. [Current state of oncolytic virotherapy in Japan].
Nakamori M; Yamaue H
Gan To Kagaku Ryoho; 2013 May; 40(5):553-8. PubMed ID: 23863576
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses.
Hadryś A; Sochanik A; McFadden G; Jazowiecka-Rakus J
Eur J Pharmacol; 2020 May; 874():172991. PubMed ID: 32044323
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.
Zhang Y; Liu Z
Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207
[TBL] [Abstract][Full Text] [Related]
37. Targeting pediatric cancer stem cells with oncolytic virotherapy.
Friedman GK; Cassady KA; Beierle EA; Markert JM; Gillespie GY
Pediatr Res; 2012 Apr; 71(4 Pt 2):500-10. PubMed ID: 22430386
[TBL] [Abstract][Full Text] [Related]
38. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
39. Radiovirotherapy: principles and prospects in oncology.
Touchefeu Y; Franken P; Harrington KJ
Curr Pharm Des; 2012; 18(22):3313-20. PubMed ID: 22397732
[TBL] [Abstract][Full Text] [Related]
40. Endothelial progenitor cells as cellular vehicles to deliver oncolytic virus therapies to metastatic tumors: the "Trojan horse" approach.
Deng W; Jia J
Med Hypotheses; 2008; 70(4):842-4. PubMed ID: 17869010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
